We previously described a laboratory developed test (LDT), OncoPrism-HNSCC, that predicts disease control with increased sensitivity and specificity compared to PD-L1 IHC for RM-HNSCC patients treated with ICIs [7, 8]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.